Grantham, Mayo, Van Otterloo & Co (GMO)
PLRX icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Pliant Therapeutics PLRX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,800
Closed -$209K – 754
2022
Q4 		$209K Buy
+10,800
New +$226K ﹤0.01% 675

Other funds holding PLRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s PLRX Position: Q1 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Pliant Therapeutics (PLRX) in Q1 2023, closing a stake of 10,800 shares — an estimated $209K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in PLRX in Q4 2022 and held it in 1 quarter. The position peaked at $209K in Q4 2022. 143 funds tracked by Wall St. Rank hold PLRX as of Q1 2023.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Pliant Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 10,800 Pliant Therapeutics shares in Q1 2023, an estimated $209K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Pliant Therapeutics in Q4 2022 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Pliant Therapeutics position peaked at $209K in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2023, filed 12 May 2023.